Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 8/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.32 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.32 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21291939 | 0.91 | SMPD1 (0.44) | LPAR3LPAR1SMPD1LPAR2CYP3A4 | |
| SCHEMBL21291955 | 0.83 | SMPD1 (0.43) | LPAR3LPAR1SMPD1LPAR2CYP3A4 | |
| SCHEMBL4940484 | 0.79 | TDP1 (0.46) | LPAR3LPAR1SMPD1LPAR2CYP3A4 | |
| SCHEMBL6445218 | 0.79 | TDP1 (0.46) | LPAR3LPAR1SMPD1LPAR2CYP3A4 | |
| SCHEMBL21291943 | 0.79 | SMPD1 (0.40) | LPAR3LPAR1SMPD1LPAR2CYP3A4 | |
| SCHEMBL8079525 | 0.78 | LPAR5 (0.46) | LPAR3LPAR1SMPD1LPAR2CYP3A4 | |
| SCHEMBL21291944 | 0.77 | SMPD1 (0.49) | LPAR3LPAR1SMPD1LPAR2LPAR5 | |
| SCHEMBL2049378 | 0.76 | SMPD1 (0.56) | LPAR3LPAR1SMPD1LPAR2CYP3A4 | |
| SCHEMBL8733936 | 0.74 | TDP1 (0.46) | LPAR3LPAR1LPAR2 | |
| SCHEMBL2520483 | 0.74 | LPAR3 (0.40) | LPAR3LPAR1SMPD1LPAR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11248011-B2 | Phosphorus-based releasing agent, optical polymerizable composition comprising same and preparation thereof | SKC CO., LTD. (KR) | 2022-02-15 | — | — | US | claimed |
| US-20190263846-A1 | PHOSPHORUS-BASED RELEASING AGENT, OPTICAL POLYMERIZABLE COMPOSITION COMPRISING SAME AND PREPARATION THEREOF | SK PUCORE CO., LTD. (KR) | 2019-08-29 | — | — | US | claimed |
| EP-3530684-A1 | PHOSPHORUS-BASED RELEASING AGENT, OPTICAL POLYMERIZABLE COMPOSITION COMPRISING SAME AND PREPARATION THEREOF | SKC Co., Ltd. (KR) | 2019-08-28 | — | — | EP | claimed |
| US-11248011-B2 | Phosphorus-based releasing agent, optical polymerizable composition comprising same and preparation thereof | SKC CO., LTD. (KR) | 2022-02-15 | — | — | US | disclosed |
| US-20190263846-A1 | PHOSPHORUS-BASED RELEASING AGENT, OPTICAL POLYMERIZABLE COMPOSITION COMPRISING SAME AND PREPARATION THEREOF | SK PUCORE CO., LTD. (KR) | 2019-08-29 | — | — | US | disclosed |
| EP-3530684-A1 | PHOSPHORUS-BASED RELEASING AGENT, OPTICAL POLYMERIZABLE COMPOSITION COMPRISING SAME AND PREPARATION THEREOF | SKC Co., Ltd. (KR) | 2019-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263846-A1 | PHOSPHORUS-BASED RELEASING AGENT, OPTICAL POLYMERIZABLE COMPOSITION COMPRISING SAME AND PREPARATION THEREOF | PMM2, PGM2, IPMK | LPAR3 2839/4885LPAR1 1995/4885SMPD1 3130/4885 |
| US-11248011-B2 | Phosphorus-based releasing agent, optical polymerizable composition comprising same and preparation thereof | PMM2, PGM2, IPMK | LPAR3 2839/4885LPAR1 1995/4885SMPD1 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.